Aberrant ALK tyrosine kinase signaling: Different cellular lineages, common oncogenic mechanisms?

American Journal of Pathology

Volumn 157, Issue 2, 2000, Pages 341-345

  Ladanyi, M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE; TROPOMYOSIN; UNCLASSIFIED DRUG;

CARCINOGENESIS; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; ENZYME ACTIVATION; GENE FUSION; MESENCHYMOMA; NOTE; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0033888914     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64545-2     Document Type: Note

References (64)

1. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
2. Molecular cytogenetics: Rosetta stone for understanding cancer
3. An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes
4. A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product
5. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
6. The NPM/ALK fusion gene in the pathogenesis of anaplastic large cell lymphoma
7. ALK lymphoma ('ALKoma'): A distinct molecular genetic subtype of non-Hodgkin lymphoma
8. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
9. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
10. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation
11. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis
12. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity
13. Role of PI-3K-AKT pathway in NPM/ALK-mediated malignant transformation of lymphoid cells
14. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)
15. Role of STAT5 in NPM/ALK-mediated malignant transformation of lymphoid cells
16. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
17. Inhibition of transforming activity of the ret/ptc 1 oncoprotein by a 2-indolinone derivative
18. Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide
19. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinico-pathologic and immunohistochemical study of 84 cases
20. Omental-mesenteric inflammatory pseudotumor. Cytogenetic demonstration of genetic changes and monoclonality in one tumor
21. Clonal changes in inflammatory pseudotumor of the lung: A case report
22. Inflammatory myofibroblastic tumor of bone: Report of two cases with evidence of clonal chromosomal changes
23. Extrapulmonary inflammatory myofibroblastic tumor: A clinical and pathological survey
24. Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: An historical review with differential diagnostic considerations
25. Inflammatory fibrosarcoma: Update, reappraisal, and perspective on its place in the spectrum of inflammatory myofibroblastic tumors
26. Comparison of DNA ploidy, histologic, and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors
27. ALK and p80 expression in inflammatory myofibroblastic tumor (IMT)
28. Anaplastic large cell lymphomas expressing the novel chimeric protein p80npm/alk: A distinct clinico-pathologic entity
29. ALK+ lymphoma: Clinico-pathological findings and outcome
30. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
31. Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity
32. Inflammatory myofibroblastic tumor with HMGIC rearrangement
33. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours
34. HMGI(Y) and HMGI-C dysregulation: A common occurrence in human tumors
35. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas
36. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: Biological, phenotypic, and clinical implications
37. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children
38. Gene rearrangement and Chernobyl related thyroid cancers
39. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas
40. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: A strong correlation between RET/PTC3 and the solid-follicular variant
41. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK
42. Translocations, cancer and the puzzle of specificity
43. Chromosomal translocations can affect genes controlling gene expression and differentiation: Why are these functions targeted?
44. c-Kit and c-kit mutations in mastocytosis and other hematological diseases
45. Gastrointestinal stromal tumors: Recent advances in understanding of their biology
46. RET proto-oncogene in the development of human cancer
47. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
48. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion. Cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma
49. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma
50. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25)
51. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation
52. Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma
53. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations
54. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma
55. Inv(2) (p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
56. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35)
57. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 Cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
58. Fusion of the EWS and CHOP genes in myxoid liposarcoma
59. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ets-family transcription factor, ERG
60. Combinatorial generation of variable fusion proteins in the Ewing family of tumours
61. Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22)
62. An RNA-binding protein gene, TLS/FUS, is fused to erg in human myeloid leukemia with t(16;21) chromosomal translocation
63. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms
64. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice